Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia
Year: 2021
Type: article
Study design: Clinical Trial
Source: Cancer
DOI: 10.1002/cncr.33469
Authors: Elias Jabbour, Koji Sasaki, Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Joseph D. Khoury, Rashmi Kanagal‐Shamanna, Jeffrey Jorgensen, Issa F. Khouri, Partow Kebriaei, Nitin Jain, Yesid Alvarado, Tapan M. Kadia, Shilpa Paul, Guillermo Garcia‐Manero, Bouthaina S. Dabaja, Jan A. Burger, Courtney D. DiNardo, Naval A. Daver, Guillermo Montalban‐Bravo, Musa Yilmaz, Maro Ohanian, Alessandra Ferrajoli, Jovitta Jacob, Meagan Rostykus, Rebecca Garris, Susan O’Brien, Hagop M. Kantarjian
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3137871084